SCHEMBL22778283

SCHEMBL22778283

Cc1ccc2c(F)c(-c3nc(-c4ccc(F)cc4)c(-c4ccncc4)[nH]3)ccc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 16/20 0.72
CSNK1D P48730 5/20 0.72
CSNK1E P49674 4/20 0.72
MAPK13 O15264 12/20 0.65
GCGR P47871 12/20 0.65
MAPK12 P53778 12/20 0.65
MAPK11 Q15759 12/20 0.65
PRKD3 O94806 2/20 0.58
MAP4K4 O95819 2/20 0.58
FRK P42685 2/20 0.58
MAPK9 P45984 2/20 0.58
CSNK1A1 P48729 2/20 0.58
GSK3B P49841 2/20 0.58
PTK6 Q13882 2/20 0.58
CLK4 Q9HAZ1 2/20 0.58
PRKD2 Q9BZL6 1/20 0.58
ALOX5 P09917 6/20 0.56
KDM4E B2RXH2 1/20 0.53
CIT O14578 1/20 0.53
GAK O14976 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29465653 0.84 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL17002321 0.84 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL21797084 0.83 MAPK14 (0.70) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL29775509 0.81 ALOX5 (0.64) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL2650684 0.80 MAPK11 (1.00) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL30365518 0.80 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL17002323 0.80 MAPK14 (1.00) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL18960515 0.79 MAPK14 (0.67) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL6960991 0.76 MAPK14 (0.72) MAPK14CSNK1DCSNK1EMAPK13GCGR
SCHEMBL5921871 0.76 MAPK14 (0.72) MAPK14CSNK1DCSNK1EMAPK13GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10865384-B2 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2020-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10865384-B2 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis CSNK1A1, CSNK1G1, CSNK2A1 MAPK14 241/4885CSNK1D 11/4885CSNK1E 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.